Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VLUBTC

(VLUBTC)

Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
07/16/20241:03AMPR Newswire (Canada)Fujitsu and Cohere launch strategic partnership and joint development to provide generative AI for enterprises
07/16/20241:03AMPR Newswire (US)Fujitsu and Cohere launch strategic partnership and joint development to provide generative AI for enterprises
07/16/20241:03AMPR Newswire (US)Tencent Cloud Maintains the position of a Challenger in the 2024 Gartner® Magic Quadrant™ for Communications Platform as a Service
07/16/20241:00AMBusiness WireSamanTree Medical Raises $14M in Series B Financing Round to Support Global Expansion and Innovation in Surgical Treatment
07/16/20241:00AMPR Newswire (US)Survey by BCT Digital and Chartis Research: Over 72% of Financial Institutions plan to invest heavily in ESG Technology
07/16/20241:00AMPR Newswire (Canada)YPO Elects Sofyan Almoayed 2024-2025 YPO Chairman
07/16/20241:00AMPR Newswire (Canada)CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe
07/16/20241:00AMPR Newswire (US)YPO Elects Sofyan Almoayed 2024-2025 YPO Chairman
07/16/20241:00AMPR Newswire (US)Allegiant Announces Eight New Routes with One-Way Fares as Low as $39*NASDAQ:ALGTAllegiant Travel Company
07/16/20241:00AMPR Newswire (US)YPO Elects Sofyan Almoayed 2024-2025 YPO Chairman
07/16/20241:00AMPR Newswire (Canada)YPO élit Sofyan Almoayed au poste de président de YPO pour 2024-2025
07/16/20241:00AMPR Newswire (US)South Korea's First Dedicated Senior Living Operator Formed
07/16/20241:00AMPR Newswire (US)CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe
07/16/20241:00AMPR Newswire (US)CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe
07/16/202412:53AMAlliance NewsAlliance NewsChina's Xi making youth unemployment a "top priority"
07/16/202412:50AMAlliance NewsAlliance NewsTrade Secretary to tell G7 "Britain is back" and "open for business"
07/16/202412:47AMAlliance NewsAlliance NewsChina, climate loom over Pacific three-day summit in Japan
07/16/202412:46AMAlliance NewsAlliance NewsTOP NEWS: Joe Biden defends "mental acuity" in feisty new interview
07/16/202412:45AMAlliance NewsAlliance NewsKretinsky-led Royal Mail bidder vows to maintain six-day serviceLSE:IDSInternational Distribution Services Plc
07/16/202412:31AMBusiness WireStart von Sodali & Co, einem neuen Unternehmen, das aus Morrow Sodali hervorgegangen ist und ein schnelles internationales Wachstum verzeichnet
07/16/202412:31AMBusiness Wire急速なグローバル成長を先駆けに、モロー・ソダリが新会社ソダリ・アンド・カンパニー(Sodali&Co)を設立
07/16/202412:30AMGlobeNewswire Inc.argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaEU:ARGXArgen X SE
07/16/202412:30AMGlobeNewswire Inc.argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaNASDAQ:ARGXargenx SE
07/16/202412:30AMBusiness WireLancement de Sodali & Co, une nouvelle société née de Morrow Sodali suite à une forte croissance internationale
07/16/202412:28AMAlliance NewsAlliance NewsGLOBAL BRIEFING: European stocks called mixed as Japan hosts summit
07/16/202412:15AMBusiness WireZai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaNASDAQ:ZLABZai Lab Ltd
07/16/202412:15AMBusiness WireZai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaNASDAQ:ARGXargenx SE
07/16/202412:10AMPR Newswire (US)HSS Ranked No. 1 in Orthopedics by U.S. News & World Report for 15th Consecutive Year, No. 3 in Rheumatology
07/16/202412:01AMBusiness WireXylazine Spreads West According to New Millennium Health Signals Alert™
07/16/202412:01AMBusiness WireNew Ivanti Research Reveals 55% of IT & Security Professionals Believe That Non-IT Leaders Don’t Understand Vulnerability Management and 47% of Leaders Agree